Systemic antibiotic therapy of acne vulgaris;Systemische antibiotika zur behandlung der acne vulgaris

JDDG - Journal of the German Society of Dermatology

Volumn 4, Issue 10, 2006, Pages 828-841

  Ochsendorf, Falk ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Acne vulgaris; Macrolides; Systemis antibiotics; Tetracyclines

Indexed keywords

ANTIANDROGEN; ANTIBIOTIC AGENT; AZELAIC ACID; AZITHROMYCIN; BENZOYL PEROXIDE; CLINDAMYCIN; COTRIMOXAZOLE; CYPROTERONE ACETATE; DOXYCYCLINE; ERYTHROMYCIN; ERYTHROMYCIN ACISTRATE; ERYTHROMYCIN STEARATE; ESTROGEN; ETHINYLESTRADIOL; GLUCONATE ZINC; GUGGULSTERONE; ISOTRETINOIN; LEVOFLOXACIN; LYMECYCLINE; MACROLIDE; MINOCYCLINE; OXYTETRACYCLINE; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETINOID; ROXITHROMYCIN; SULFAMETHOXAZOLE; TETRACYCLINE; TRIMETHOPRIM; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACNE VULGARIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANOSMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BLOATING; BRAIN PSEUDOTUMOR; BREAST TENSION; CANDIDIASIS; CHOLESTATIC HEPATITIS; COLIC; DIARRHEA; DIPLOPIA; DISEASE EXACERBATION; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRY SKIN; DYSMENORRHEA; DYSPEPSIA; EOSINOPHILIA; ERYTHEMA; ERYTHEMA MULTIFORME; ESOPHAGITIS; EXFOLIATIVE DERMATITIS; GASTROINTESTINAL SYMPTOM; HEARING LOSS; HEPATITIS; HUMAN; HYPERPIGMENTATION; HYPERSENSITIVITY REACTION; HYPERTENSION; IMPETIGO; KIDNEY FAILURE; LETHARGY; LUPUS LIKE SYNDROME; MASTALGIA; MEDICAL LITERATURE; MENSTRUAL IRREGULARITY; MYASTHENIA GRAVIS; NAUSEA; OTOTOXICITY; PANCREATITIS; PHOTOTOXICITY; PNEUMONIA; POLYARTERITIS NODOSA; POLYARTHRITIS; PSEUDOMEMBRANOUS COLITIS; REVIEW; SERUM SICKNESS; SKIN ALLERGY; SKIN BURNING SENSATION; SKIN IRRITATION; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; THYROIDITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VAGINA DISCHARGE; VAGINAL DISCOMFORT; VASCULITIS; VOMITING;

ACNE VULGARIS; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES;

EID: 33748924512     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2006.06053.x     Document Type: Review

References (59)

1. Stern RS. Medication and medical service utilization for acne 1995-1998. J Am Acad Dermatol 2000; 43: 1042-8.
2. Gollnick H, Cunfliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita AR, Thiboutot D. Management of Acne: A report form a global alliance to improve outcomes in acne. J Am Acad Dermatol 2003; 49 (Suppl.1): S1; S 37.
3. Dreno B, Bettoli V, Ochsendorf F, Layton A, Mobacken H, Degreef H:. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol 2004; 14: 391-9.
4. Thielitz A, Gollnick H. Systemische Aknetherapie. J Dtsch Dermatol Ges 2005; 3: 366-78.
5. Jappe U. Akne und Propionibakterien. Deutscher Dermatologe 2002: 583-9.
6. De Young LM, Young JM, Ballaron SJ, Spires DA, Puhvel SM.. Intradermal injection of Propionibacterium acnes: a model of inflammation relevant to acne. J Invest Dermatol 1984; 83: 394-8.
7. Kirschbaum JD, Kligman AM. The pathogenic role of Corynebacterium acnes in acne vulgaris. Arch Dermatol 1963; 88: 832-3.
8. Leeming JP, Holland KT, Cunliffe WJ. The microbial colonization of inflamed acne vulgaris lesions. Br J Dermatol 1988; 18: 205-8.
9. Skidmore R, Kovach R, Walker C, Thomas J, Bradshaw M, Leyden J, Powala C, Ashley R. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003; 139: 459-64.
10. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 2005; 153: 395-403.
11. Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003; 121: 20-7.
12. Mouser PE, Baker BS, Seaton ED, Chu AC. Propionibacterium acnes-reactive T helper-1 cells in the skin of patients with acne vulgaris. J Invest Dermatol 2003; 121: 1226-8.
13. Graham GM, Farrar MD, Cruse-Sawyer JE, Holland KT, Ingham E. Proinflammatory cytokine production by human keratinocytes stimulated with propionibacterium acnes and P. acnes GroEL. Br J Dermatol 2004; 150: 421-8.
14. Schaller M, Loewenstein M, Borelli C, Jacob K, Vogeser M, Burgdorf WH, Plewig G. Induction of a chemoattractive proinflammatory cytokine response after stimulation of keratinocytes with Propionibacterium acnes and coproporphyrin III. Br J Dermatol 2005; 153: 66-71.
15. Sunderkötter C, Herrmann M, Jappe U. Antimikrobielle Therapie in der Dermatologie. J Dtsch Dermatol Ges 2006; 4: 10-27.
16. Brinkmeier T, Frosch PJ. Orale Antibiotika mit antiinflammatorischer/ immunmodulatorischer Wirkung für die Therapie verschiedener Dermatosen. Hautarzt 2002; 53: 456-65.
17. Akamatsu H, Tomita T, Horio T. Effects of Roxithromycin on the production of lipase and neutrophil chemotactic factor by Propionibacterium acnes. Dermatology 2002; 204: 277-80.
18. Jain A, Sangal L, Basal E, Kaushal GP, Agarwal SK. Anti-inflammatory effects of Erythromycin and Tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatology Online Journal 2002; 8: 2.
19. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54: 258-65.
20. Report AHC. Systemic antibiotics for treatment of acne vulgaris: efficacy and safety. Arch Dermatol 1975; 111: 1630-6.
21. Lehmann HP, Robinson KA, Andrews JS, Holloway V, Goodman SN. Acne therapy: a methodologic review. J Am Acad Dermatol 2002; 47: 231-40.
22. Garner SE, Eady EA, Popescu C, Newton J, Li Wan Po A. Minocycline for acne vulgaris: efficacy and safety (Cochrane Review). In: The Cochrane Library, Issue 3 edn.: Oxford: Update Software, 2002.
23. Lehmann HP, Andrews JS, Robinson KA, et al. Management of Acne (Evidence Report/Technology Assessment No. 17 (Prepared by Johns Hopkins Evidence-based Practice Center under Contract No. 290-97-006). Rockville, MD: Agency for Healthcare Research and Quality; HRQ Publication No. 01-E019., 2001.
24. Ozolins M, Eady AE, Avery AJ, Cunfliffe WJ, Li Wan Po A, O'Neill C, Simpson NB, Walters CE, Carnegie E, Lewis JB, Dada J, Haynes M, Williams K, Williams HC. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: a randomised controlled trial. Lancet 2004; 364: 2188-95.
25. Cunliffe W, Meynadier J, Alirezai M, George SA, Coutts I, Roseeuw D, Hachem JP, Briantais P, Sidou F, Soto P. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1 %, versus lymecycline plus gel vehicle. J Am Acad Dermatol 2003; 49 (Suppl.3): S218-26.
26. Akamatsu H, Nishijima S, Akamatsu M, Kurokawa I, Asada Y.. Clinical evaluation of roxithromycin in patients with acne. J Int Med Res 1996; 24: 109-14.
27. Ferahbas A, Utas S, Aykol D, Borlu M, Uksal U. Clinical evaluation of roxithromycin: a double-blind, placebo-controlled and crossover trial in patients with acne vulgaris. J Dermatol 2004; 31: 6-9.
28. Parsad D, Pandhi R, Nagpal R, Negi KS. Azithromycin monthly pulse vs daily doxycycline in the treatment of acne vulgaris. J Dermatol 2001; 28: 1-4.
29. Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol 2005; 30: 215-20.
30. Kawada A, Aragane Y, Tezuka T. Levofloxacin is effective for inflammatory acne and achieves high levels in the lesions: an open study. Dermatology 2002; 204: 301-2.
31. Cunliffe WJ. Evolution of a strategy for the treatment of acne. J Am Acad Dermatol 1987; 16: 591-9.
32. Hughes BR, Murphy cE, Barnett J, Cunliffe WJ. Strategy of acne therapy with long-term antibiotics. Br J Dermatol 1989; 121: 623-8.
33. Christiansen JV, Gadborg E, Ludvigsen K, Konstman Meier CH, Norholm A, Osmundsen PE, Pedersen D, Rasmussen KA, Reiter H, Reymann F, Rosman N, Sylvest B, Unna P, Wehnert R, Aastrup B, Andersen B, Holm P. Topical vitamin A acid (Airol) and systemic oxytetracycline in the treatment of acne vulgaris. A controlled clinical trial. Dermatologica 1974; 149: 121-8.
34. Mills OHJ, Marples RR, Kligman AM. Acne vulgaris. Oral therapy with tetracycline and topical therapy with vitamin A. Arch Dermatol 1972; 106: 200-3.
35. Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Arsonnaud S, Kang S. Combination therapy with adapalene gel 0.1 % and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed 2005; 4: 138-46.
36. Gollnick HP, Graupe K, Zaumseil RP. Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol 2001; 11: 538-44.
37. Greenwood R, Brummitt L, Burke B, Cunliffe WJ. Acne: double blind clinical and laboratory trial of tetracycline, oestrogen-cyproterone acetate, and combined treatment. Br Med J (Clin Res Ed) 1985; 291: 1231-5.
38. Wong RC, Kang S, Heezen JL, Voorhees JJ, Ellis CN. Oral ibuprofen and tetracycline for the treatment of acne vulgaris. J Am Acad Dermatol 1984; 11: 1076-81.
39. Pierard-Franchimont C, Goffin V, Arrese JE, Martalo O, Braham C, Slachmuylders P, Pierard GE. Lymecycline and minocycline in inflammatory acne: a randomized, double-blind intent-to-treat study on clinical and in vivo antibacterial efficacy. Skin Pharmacol Appl Skin Physiol 2002; 15: 112-9.
40. Layton AM, Hughes BR, Hull SM, Eady EA, Cunliffe WJ.. Seborrhoea - an indicator for poor clinical response in acne patients treated with antibiotics. Clin Exp Dermatol 1992; 17: 173-5.
41. Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? Implications of resistance for acne patients and prescribers. Am J Clin Dermatol 2003; 4: 813-31.
42. Mobacken H. [Oral tetracycline - treatment of acne. Rapid facial improvement, but back lesions are more difficult to treat]. Lakartidningen 1993; 90: 2755-7.
43. Campo M, Zuluaga A, Escobar P, et al. A comparative study on the effectiveness of lymecrcline and adapalene versus minocycline and adapalene in the treatment of acne vulgaris. In: Proceedings 20th World Congress of Dermatology. 1-5 July 2002. Paris, France, 2002: P0005.
44. Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, Tosti G, Katsambas A, Galvan Perez Del Pulgar JI, Rollman O, Torok L, Eady EA, Cove JH. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003; 148: 467-78.
45. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003; 206: 54-6.
46. Levy RM, Huang EY, Roling D, Leyden JJ, Margolis DJ. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol 2003; 139: 467-71.
47. Grasset L, Guy C, Ollagnier M. [Cyclines and acne: pay attention to adverse drug reactions! A recent literature review]. Rev Med Interne 2003; 24: 305-16.
48. Ayangco L, Sheridan PJ. Minocycline-induced staining of torus palatinus and alveolar bone. J Periodontol 2003; 74: 669-71.
49. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 1996; 134: 695.
50. Margolis DJ, Bowe WP, Hoffstad O, Berlin JA. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol 2005; 141: 1132-6.
51. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline and doxycycline. Arch Dermatol 1997; 133: 1224-30.
52. Schlienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus: a systematic review. Dermatology 2000; 200: 223-31.
53. Meynadier J, Alirezai M. Systemic antibioitics for acne. Dermatology 1998; 196: 135-9.
54. Layton AM, Cunfliffe W. Phototoxic eruptions due to doxycycline - a dose-related phenomenon. Clin Exp Dermatol 1993; 18: 425-7.
55. Carroll LA, Laumann AE. Doxycycline-induced photo-onycholysis. J Drugs Dermatol 2003; 2: 662-3.
56. Lim DS, Murphy GM. High-level ultraviolet A photoprotection is needed to prevent doxycycline phototoxicity: lessons learned in East Timor. Br J Dermatol 2003; 149: 213-4.
57. ACOG. The use of hormonal contraception in women with coexisting medical conditions. ACOG Prac Bull 2000; 18: 1-13.
58. Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol 2002; 46: 917-23.
59. Samuelson JS. An accurate photographic method for grading acne: initial use in a double-blind clinical comparison of minocycline and tetracycline. J Am Acad Dermatol 1985; 12: 461-7.